Mirae Asset Global Investments
DNLI icon

Mirae Asset Global Investments’s Denali Therapeutics DNLI Stock Holding History

Mirae Asset Global Investments’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$183K Sell
7,098
-1,174
-14% -$24.1K ﹤0.01% 1136
2026
Q1 		$159K Buy
8,272
+1,145
+16% +$22.8K ﹤0.01% 1100
2025
Q4 		$118K Buy
7,127
+1,474
+26% +$24.9K ﹤0.01% 1231
2025
Q3 		$82.1K Buy
5,653
+41
+0.7% +$589 ﹤0.01% 1258
2025
Q2 		$78.5K Buy
5,612
+753
+15% +$10.6K ﹤0.01% 1179
2025
Q1 		$71.8K Buy
4,859
+63
+1% +$1.21K ﹤0.01% 1171
2024
Q4 		$98.8K Sell
4,796
-382
-7% -$9.78K ﹤0.01% 1148
2024
Q3 		$152K Buy
5,178
+920
+22% +$22.8K ﹤0.01% 1132
2024
Q2 		$97.8K Sell
4,258
-66,884
-94% -$1.28M ﹤0.01% 1147
2024
Q1 		$1.58M Sell
71,142
-2,443
-3% -$45.9K ﹤0.01% 1317
2023
Q4 		$1.58M Buy
73,585
+3,911
+6% +$77.5K ﹤0.01% 1373
2023
Q3 		$1.44M Sell
69,674
-4
-0% -$101 ﹤0.01% 1342
2023
Q2 		$2.05M Buy
69,678
+2,700
+4% +$75.9K ﹤0.01% 1200
2023
Q1 		$1.54M Buy
66,978
+12,371
+23% +$340K ﹤0.01% 1337
2022
Q4 		$1.52M Buy
54,607
+5,709
+12% +$170K ﹤0.01% 1289
2022
Q3 		$1.5M Buy
48,898
+13,664
+39% +$444K ﹤0.01% 1270
2022
Q2 		$1.04M Buy
+35,234
New +$923K ﹤0.01% 1382
2021
Q4 		– Sell
-7,017
Closed -$354K – 1621
2021
Q3 		$354K Buy
7,017
+1,161
+20% +$65.4K ﹤0.01% 1577
2021
Q2 		$460K Buy
+5,856
New +$362K ﹤0.01% 1470

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments's DNLI Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Denali Therapeutics (DNLI) stake by 14% in Q2 2026, selling an estimated $24.1K and leaving 7,098 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #1136.

Mirae Asset Global Investments first reported a position in DNLI in Q2 2021 and has held it in 19 quarters since. The position peaked at $2.05M in Q2 2023. 112 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Mirae Asset Global Investments held 7,098 shares of Denali Therapeutics worth $183K as of Q2 2026.
  • Mirae Asset Global Investments sold 1,174 Denali Therapeutics shares in Q2 2026, an estimated $24.1K.
  • Denali Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1136 holding.
  • Mirae Asset Global Investments first reported a position in Denali Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Mirae Asset Global Investments's Denali Therapeutics position peaked at $2.05M in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.